Adamis Pharma Received FDA Approval on Labeling for Symjepi 0.3MG/0.3ML (0.3MG/0.3ML); 0.15MG/0.3ML (0.15MG/0.3ML)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207534
Altimmune Says Has Been Unable To enroll Subjects In Final Cohort Of T-COVID Study, Will Terminate Further Enrollment And Evaluate Options For T-COVID
T-COVID Update
The Phase 1/2 trial completed dosing in 2 of the 3 planned dose cohorts. The first 2 cohorts were designed to assess the safety of T-COVID treatment and were comprised of COVID-19 infected patients 49
Angion Announces Phase 2 ALI-201 Study Did Not Meet Primary Or Secondary Efficacy Endpoint
Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic
Why Shares Of MediWound And Vericel Fell On Tuesday
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application.
Agenus Publishes Clinical Trial Titled ‘Balstilimab in Patients With Recurrent Cervical Cancer.’ To ClinicalTrials.Gov Site
https://clinicaltrials.gov/ct2/show/NCT04943627
Rafael Holdings Says FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For CPI-613 For Treatment Of Biliary Cancer
Rafael Pharmaceuticals, Inc. ("Rafael" or the "Company"), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA)
‘Adjuvant Developed with NIH Funding Enhances Efficacy of India’s COVID-19 Vaccine’ -NIAID Report. BZ NOTE: Occugen Is A Partner With India’s Bharat Biotech, Which Will Be Providing Many Of The Nation’s COVID-19 Vaccines
https://www.niaid.nih.gov/news-events/adjuvant-developed-nih-funding-enhances-efficacy-indias-covid-19-vaccine
FDA Strikes Off MediWound – Vericel’s NexoBrid Biologics License Application; Stocks Drop
Vericel Corporation’s (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar…
Merck’s Keytruda-Chemo Combo Wins European Approval In Esophagus Cancer
The European Commission has approved Merck & Co Inc’s (NYSE:MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment…